

# Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues

Qi Chen<sup>\*†</sup>, Michael Graham Espey<sup>‡</sup>, Murali C. Krishna<sup>‡</sup>, James B. Mitchell<sup>‡</sup>, Christopher P. Corpe<sup>\*</sup>, Garry R. Buettner<sup>§</sup>, Emily Shacter<sup>†</sup>, and Mark Levine<sup>\*¶</sup>

<sup>\*</sup>Molecular and Clinical Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892; <sup>‡</sup>Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; <sup>§</sup>Free Radical and Radiation Biology Program, University of Iowa, Iowa City, IA 52242-1101; and <sup>¶</sup>Laboratory of Biochemistry, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892

Communicated by J. E. Rall, National Institutes of Health, Bethesda, MD, August 2, 2005 (received for review June 1, 2005)

Human pharmacokinetics data indicate that i.v. ascorbic acid (ascorbate) in pharmacologic concentrations could have an unanticipated role in cancer treatment. Our goals here were to test whether ascorbate killed cancer cells selectively, and if so, to determine mechanisms, using clinically relevant conditions. Cell death in 10 cancer and 4 normal cell types was measured by using 1-h exposures. Normal cells were unaffected by 20 mM ascorbate, whereas 5 cancer lines had EC<sub>50</sub> values of <4 mM, a concentration easily achievable i.v. Human lymphoma cells were studied in detail because of their sensitivity to ascorbate (EC<sub>50</sub> of 0.5 mM) and suitability for addressing mechanisms. Extracellular but not intracellular ascorbate mediated cell death, which occurred by apoptosis and pyknosis/necrosis. Cell death was independent of metal chelators and absolutely dependent on H<sub>2</sub>O<sub>2</sub> formation. Cell death from H<sub>2</sub>O<sub>2</sub> added to cells was identical to that found when H<sub>2</sub>O<sub>2</sub> was generated by ascorbate treatment. H<sub>2</sub>O<sub>2</sub> generation was dependent on ascorbate concentration, incubation time, and the presence of 0.5–10% serum, and displayed a linear relationship with ascorbate radical formation. Although ascorbate addition to medium generated H<sub>2</sub>O<sub>2</sub>, ascorbate addition to blood generated no detectable H<sub>2</sub>O<sub>2</sub> and only trace detectable ascorbate radical. Taken together, these data indicate that ascorbate at concentrations achieved only by i.v. administration may be a pro-drug for formation of H<sub>2</sub>O<sub>2</sub>, and that blood can be a delivery system of the pro-drug to tissues. These findings give plausibility to i.v. ascorbic acid in cancer treatment, and have unexpected implications for treatment of infections where H<sub>2</sub>O<sub>2</sub> may be beneficial.

cell death | ascorbate radical

Ascorbic acid (vitamin C, ascorbate) has a controversial history in cancer treatment (1). Observational reports described ascorbate, given in pharmacologic doses of 10 g daily, as effective in treating some cancers and in improving patient well-being (2–4). Subsequently, the same dose had no effect on patient well-being and survival in two double-blind placebo-controlled trials, and ascorbate was discarded as a treatment modality (5, 6). Recent clinical evidence, however, indicates that the role of ascorbate in cancer treatment should be examined anew (7). The originally reported observational studies used i.v. and oral ascorbate, but the subsequent double-blind placebo-controlled studies used only oral ascorbate. It was not recognized that the route of ascorbate administration might produce large differences in plasma concentrations. Recent pharmacokinetics studies in men and women show that 10 g of ascorbate given i.v. is expected to produce plasma concentrations of nearly 6 mM, which are >25-fold higher than those concentrations from the same oral dose (7–9). As much as a 70-fold difference in plasma concentrations is expected between oral and i.v. administration, depending on dose. Despite inconsistencies, some *in vitro* studies showed that ascorbate killed cancer cells, although mechanisms and physiologic relevance were unclear

(10–12). Complementary and alternative medicine practitioners worldwide currently use ascorbate i.v. in some patients, in part because there is no apparent harm (13–15).

Given its potential safety and benefit, there is merit in investigating i.v. ascorbate as a possible novel cancer treatment modality. It is essential first to learn whether ascorbate acts as an anticancer agent *in vitro*, and if so, by what mechanisms. Our goals were to address the following: Does ascorbate in pharmacologic concentrations kill cancer cells, but not normal cells, using conditions that mimic i.v. use and a clinically relevant time course? Is action dependent on extracellular ascorbate, intracellular ascorbate, or both? If effective, what are the mechanisms? Can ascorbate be delivered to tissues without harm? Are there implications for other diseases?

We studied ascorbate at physiologic (0.1 mM) and pharmacologic (0.3–20 mM) concentrations using 1-h incubations to mimic clinical i.v. use (7–9). The data showed that pharmacologic concentrations of ascorbate killed cancer but not normal cells, that cell death was dependent only on extracellular but not intracellular ascorbate, and that killing was dependent on extracellular hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) formation with ascorbate radical as an intermediate. Ascorbate generated detectable levels of H<sub>2</sub>O<sub>2</sub> in extracellular medium in the presence of trace serum protein but not in whole blood. The findings indicate that ascorbate at pharmacologic concentrations in blood may be a pro-drug for H<sub>2</sub>O<sub>2</sub> delivery to tissues, with major therapeutic implications.

## Materials and Methods

**Cells and Reagents.** Human Burkitt's lymphoma cells (JLP-119) were obtained and studied as described in ref. 16. Other cell lines were purchased from American Type Culture Collection and were grown at 37°C in 5% CO<sub>2</sub>/95% air in recommended media containing 10% FBS (GIBCO). Human lymphocytes and monocytes were isolated by apheresis (17) from at least six healthy subjects and used immediately. Ascorbic acid was always buffered to pH 7.0 with sodium hydroxide and prepared immediately before use. Dehydroascorbic acid was freshly prepared (18). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from Molecular Probes and bacto-agar was from Difco. Other reagents, enzymes, and media were from general commercial sources.

**Cell Death.** Nuclear staining with Hoechst 33342 (Hoechst Pharmaceuticals) and propidium iodide (PI) was used for morphological

Abbreviations: MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PI, propidium iodide.

<sup>¶</sup>To whom correspondence should be addressed at: Molecular and Clinical Nutrition Section, National Institutes of Health, Building 10, Room 4D52, MSC-1372, Bethesda, MD 20892-1372. E-mail: markl@mail.nih.gov.

© 2005 by The National Academy of Sciences of the USA

assessment of apoptosis, necrosis, and pyknosis/necrosis by fluorescence microscopy as described in ref. 19. Briefly,  $2.5 \times 10^5$  cells per ml were incubated with ascorbate or  $H_2O_2$  for 1 h, washed with PBS, and suspended in fresh media. After 18–22 h, at least 200 cells were stained with Hoechst/PI and visualized under fluorescence microscopy.

MTT was used as a screening assay and performed as described in ref. 20. Cells in 96-well plates were treated with ascorbate (0.1–20 mM) for 1 h, washed, and incubated for an additional 24 h. The  $EC_{50}$  value was the concentration that reduced survival by 50%.

For colony formation on soft agar plates, cells were treated with 5 mM ascorbate for 1 h, washed, and plated. A two-layer agar system was used, and colonies were visualized after 10–14 days (21).

To determine the effects of red blood cells on ascorbate-induced cell death, red blood cells were prepared by centrifugation of heparinized human blood at  $500 \times g$  for 30 min. Human Burkitt's lymphoma cells at  $2.5 \times 10^5$  cells per ml were mixed with red blood cells, 25% or 50% hematocrit. Cell mixtures were treated with 2 mM ascorbate for 1 h. Lymphoma cells were recovered by using Vacutainer CPT tubes (Becton Dickinson) according to the manufacturer's instructions. After washing, lymphoma cells were returned to fresh medium and assessed after 18 h by nuclear staining as above.

**Quantitative Procedures.** Catalase activity was determined by using Amplex Red (Molecular Probes) (22). Glutathione was detected by using 5,5'-dithio bis-2-nitrobenzoic acid, and glutathione peroxidase activity was measured by a coupled reaction with glutathione reductase (Cayman Chemical, Ann Arbor, MI), according to the manufacturer's instructions.


Ascorbate radical in culture media and blood was detected by using electron paramagnetic resonance (23, 24). Spectrometer (E9 series, Varian) settings were as follows: microwave power, 20 mW; modulation amplitude, 1.0 G; time constant, 0.25 s; scan range,  $4 \times 10$  G; and scan time, 4 min. Radical quantitation was performed by using 3-carboxyproxyl as a standard (23).

Because ascorbate interferes with most peroxidase-based detection methods,  $H_2O_2$  was measured by using a Clark-type oxygen electrode (5/6 Oxygraph, Gilson Medical Electronics, Middleton, WI). Oxygen evolution was measured upon introduction of catalase:  $2H_2O_2 \rightarrow 2H_2O + O_2$ . Calibration was performed with freshly prepared solutions of  $H_2O_2$  (10–200  $\mu M$ ) (25).

Ascorbate was measured by HPLC with coulometric electrochemical detection (26). Protein was determined by using bicinchoninic acid (27). Cell volumes were determined by using a Coulter Multisizer II cell counter. Intracellular ascorbate concentrations were calculated by converting cell protein to a measured intracellular volume (18).

## Results

**Effects of Ascorbic Acid in Pharmacologic Concentrations on Survival of Tumor and Normal Cells.** We first investigated whether ascorbate in pharmacologic concentrations selectively affected the survival of cancer cells by studying nine cancer cell lines, four normal cell types, and clinically relevant conditions. Clinical pharmacokinetics analyses show that pharmacologic concentrations of plasma ascorbate, from 0.3 to 15 mM, are achievable only from i.v. administration (7). These concentrations are cleared within hours by renal filtration and excretion. In contrast, plasma ascorbate concentrations from maximum possible oral doses cannot exceed 0.22 mM because of limited intestinal absorption, which is bypassed with i.v. administration (7–9). To mimic potential clinical i.v. use, tested cells were incubated for 1 h with either pharmacologic ascorbate concentrations (0.3–20 mM) or a high physiologic concentration (0.1 mM) as control. Once ascorbate was removed, cell survival was determined by nuclear staining or MTT after 24 h (Fig. 1A). For five of the nine cancer cell lines, ascorbate concentrations causing a 50% decrease in cell survival ( $EC_{50}$  values) were less than 5 mM, a concentration



**Fig. 1.** Effects of pharmacologic ascorbic acid concentrations on cancer and normal cells. Concentrations in this and all figures indicate final concentrations. (A)  $EC_{50}$  values of ascorbate in human and mouse cancer cells and normal human cells. All cells were treated with ascorbate for 1 h, washed, and recultured without ascorbate.  $EC_{50}$  values were determined 18–22 h later by using Hoechst/PI for human Burkitt's lymphoma cells (JLP119), MTT and Hoechst/PI for normal lymphocytes and monocytes, and MTT for all other cells (see *Materials and Methods*). (B) Colony formation of cancer cells in soft agar after a 1-h treatment with 5 mM ascorbate. Surviving fraction, expressed in log scale, indicates the number of treated colonies compared with matched untreated control cells.

easily achievable from i.v. infusion (7). All tested normal cells were insensitive to 20 mM ascorbate.


Colony formation assays were used as an additional means to determine cell survival (21). Four cancer cell lines were incubated with 5 mM ascorbate or untreated media for 1 h. Cells were diluted and plated and growth assessed after 14 days (Fig. 1B). All four untreated cell lines grew in soft agar, whereas three of four exposed to ascorbate displayed at least 99% growth inhibition.

**Effects of Ascorbic Acid on Death of Human Lymphoma Cells.** Human lymphoma cells (JLP-119) were studied in detail to determine the effects of ascorbate on cell death. Lymphoma cells were selected because of their sensitivity to ascorbate (Fig. 1A), the suitability of these cells for nuclear staining to characterize the mode of cell death (16, 19, 28), and the report of a positive clinical response of lymphoma to i.v. ascorbate (14) (unpublished work). Cells were incubated for 1 h with 0.1–5 mM ascorbate and washed, and Hoechst/PI nuclear staining was performed 18 h later to determine the amount and type of cell death (Fig. 2A). Ascorbate induced concentration-dependent cell death, which was nearly 100% at 2 mM. As ascorbate concentration increased, the pattern of death changed from apoptosis to pyknosis/necrosis, a pattern suggestive of  $H_2O_2$ -mediated cell death (19). We determined the time necessary for cell death after exposure to 2 mM ascorbate for 1 h (Fig. 2B). Apoptosis occurred by 6 h after exposure, and cell death by pyknosis was  $\approx 90\%$  at 14 h after exposure. In contrast to lymphoma cells, there was little or no killing of normal lymphocytes and monocytes by ascorbate (Fig. 2C).

The roles of intracellular versus extracellular ascorbate in causing cell death were examined, using ascorbate and its oxidized product dehydroascorbic acid. Ascorbate is transported into cells as such by sodium-dependent transporters, whereas dehydroascorbic acid is transported into cells by glucose transporters and then immediately reduced internally to ascorbate (29). By using either external ascorbate or external dehydroascorbic acid, lymphoma cells were loaded to equal internal concentrations of ascorbate over 1 h (data







**Fig. 5.** Human blood inhibits H<sub>2</sub>O<sub>2</sub> and ascorbate radical generation from ascorbate. Ascorbate radical was measured by electron paramagnetic resonance, H<sub>2</sub>O<sub>2</sub> was measured by oxygen electrode, and cell death was measured and displayed as in Fig. 2. (A) Ascorbate radical formation as function of ascorbate concentrations added to blood (◆) or medium (▲). (B) H<sub>2</sub>O<sub>2</sub> generated by ascorbate concentrations added to blood (◆) or medium (▲) (1-h incubation), and H<sub>2</sub>O<sub>2</sub> measured in blood immediately after the addition of indicated concentrations (△). (C) Human Burkitt's lymphoma cell death in the presence or absence of red blood cells (RBC) at 25% or 50% hematocrit (HCT) (2 mM ascorbate, 1-h treatment).

ated by ascorbate oxidation. Control formation of H<sub>2</sub>O<sub>2</sub> as a function of ascorbate concentration in medium proceeded as expected. These data indicate that even if ascorbate radical was formed in blood and H<sub>2</sub>O<sub>2</sub> was generated, it would be immediately scavenged to concentrations below detection limits. Based on these data, an additional functional experiment was conducted, based on the prediction that blood would protect tumor cells from ascorbate-mediated cell death. Lymphoma cells were incubated in the presence or absence of red blood cells, with and without added ascorbate. Red blood cells completely protected lymphoma cells from ascorbate-mediated cell death (Fig. 5C). Taken together, these data indicate that ascorbate cannot generate sustainable H<sub>2</sub>O<sub>2</sub> concentrations in whole blood. The data are consistent with the hypothesis that ascorbate in pharmacologic concentrations is a pro-drug for H<sub>2</sub>O<sub>2</sub> generation in the extracellular milieu but not in blood.

## Discussion

Our data show that ascorbic acid selectively killed cancer but not normal cells, using concentrations that could only be achieved by i.v.

administration and conditions that reflect potential clinical use. The effect was due only to extracellular and not intracellular ascorbate, consistent with clinical i.v. dosing. Ascorbate-mediated cell death was due to protein-dependent extracellular H<sub>2</sub>O<sub>2</sub> generation, via ascorbate radical formation from ascorbate as the electron donor. Like glucose, when ascorbate is infused i.v., the resulting pharmacologic concentrations should distribute rapidly in the extracellular water space (42). We showed that such pharmacologic ascorbate concentrations in media, as a surrogate for extracellular fluid, generated ascorbate radical and H<sub>2</sub>O<sub>2</sub>. In contrast, the same pharmacologic ascorbate concentrations in whole blood generated little detectable ascorbate radical and no detectable H<sub>2</sub>O<sub>2</sub>. These findings can be accounted for by efficient and redundant H<sub>2</sub>O<sub>2</sub> catabolic pathways in whole blood (e.g., catalase and glutathione peroxidase) relative to those in media or extracellular fluid (38–41). The totality of the data are consistent with the interpretation that ascorbic acid administered i.v. in pharmacologic concentrations may serve as a pro-drug for H<sub>2</sub>O<sub>2</sub> delivery to the extracellular milieu, but without H<sub>2</sub>O<sub>2</sub> accumulation in blood.

Although it is possible that H<sub>2</sub>O<sub>2</sub> might accumulate in blood, this would occur only under specific conditions that reflect on the general safety of i.v. ascorbate. Ascorbate administered i.v. is likely to be safe in most patients, with virtually no toxicity compared to most currently available cancer chemotherapeutic agents. The occurrence of one predicted complication, oxalate kidney stones, is controversial (13). In patients with glucose-6-phosphate dehydrogenase deficiency, i.v. ascorbate is contraindicated because it causes intravascular hemolysis (13). The mechanism of this previously unexplained observation is now straightforward, based on the results here. H<sub>2</sub>O<sub>2</sub> generated in blood is normally removed by catalase and glutathione peroxidase within red blood cells, with internal glutathione providing reducing equivalents. The electron source for glutathione is NADPH from the pentose shunt, via glucose-6-phosphate dehydrogenase. If activity of this enzyme is diminished, the predicted outcome is impaired H<sub>2</sub>O<sub>2</sub> removal causing intravascular hemolysis, the observed clinical finding.

Ascorbate as a potential cancer therapeutic agent has a controversial and emotionally charged past (1, 3–6). Clinical observational studies reported possible benefit in selected patients, but double-blind placebo-controlled studies reported no benefit, and ascorbate was discarded as a potential therapy by conventional practitioners. Only recently has it been understood that the discordant clinical findings can be explained by previously unrecognized fundamental pharmacokinetics properties of ascorbate (7). *In vitro* effects of ascorbate on death and survival of cell lines have been reported, but there are multiple experimental concerns. For example, reports compared an experimental condition to that with no ascorbate at all (43, 44), but such a condition has had unclear physiologic relevance, because ascorbate outside and inside cells is always present unless there is severe scurvy. It was unclear whether observed effects were due to extracellular or intracellular ascorbate, or both (12, 43–46). Some experiments have used widely varying incubation times and ascorbate concentrations that have had no corresponding clinical context, making interpretation difficult. H<sub>2</sub>O<sub>2</sub> generation by ascorbate oxidation in culture media was variously interpreted as artifact (47, 48), even though chelators had no effect (49), or reported to mediate damage internally due to diminished intracellular ascorbate, but using an H<sub>2</sub>O<sub>2</sub> assay in which ascorbate could interfere (43, 44).

The experiments presented here provide a clear clinical context for ascorbate action. Conditions were selected to reflect peak ranges of i.v. ascorbate concentrations, which clinically might last a few hours at most, depending on the infusion rate (7). Intracellular transport of ascorbate is tightly controlled in relation to extracellular concentration (8, 9, 29). Intravenous ascorbate infusion is expected to drastically change extracellular but not intracellular concentrations (8, 9). For i.v. ascorbate to be clinically useful in killing cancer cells, pharmacologic but not physiologic extracellular

concentrations should be effective, independent of intracellular ascorbate concentrations. This was what was observed here. The experiments here provide a cohesive explanation for ascorbate action in generating H<sub>2</sub>O<sub>2</sub> outside cells, without H<sub>2</sub>O<sub>2</sub> accumulation in blood, leading to the conclusion that ascorbate at pharmacologic concentrations in blood is a pro-drug for H<sub>2</sub>O<sub>2</sub> delivery to tissues.

We observed that H<sub>2</sub>O<sub>2</sub> generation was independent of metal chelators and dependent on at least 0.5% extracellular protein. The responsible proteins were between 10 and 30 kDa (data not shown). It is reasonable that extracellular milieu contains these proteins, given that extracellular milieu is as much as 20% of serum protein, and favors lower-molecular-weight proteins (50). Although identities of the proteins responsible are unknown, we postulate that they may have redox-active metal centers. While chelators may marginally affect these metals, they could participate in the oxidation of ascorbate when it is at pharmacologic concentrations, with subsequent formation of superoxide and H<sub>2</sub>O<sub>2</sub> (34). It is also possible that *in vivo*, cell membranes and their associated proteins could harbor metals accessible to extracellular fluid and could react similarly. In either case, ascorbate, an electron-donor in such reactions, ironically initiates pro-oxidant chemistry and H<sub>2</sub>O<sub>2</sub> formation (34, 51).

It is unknown why ascorbate, via H<sub>2</sub>O<sub>2</sub>, killed some cancer cells but not normal cells. There was no correlation with ascorbate-induced cell death and glutathione, catalase activity, or glutathione peroxidase activity. The data here showed that ascorbate initiated H<sub>2</sub>O<sub>2</sub> formation extracellularly, but H<sub>2</sub>O<sub>2</sub> targets could be either intracellular or extracellular, because H<sub>2</sub>O<sub>2</sub> is membrane permeant (38, 52). For example, extracellular H<sub>2</sub>O<sub>2</sub> might target membrane lipids, forming hydroperoxides or reactive intermediates that are quenched or repaired in normal cells but not in sensitive cancer cells. In sensitive but not resistant cancer cells, intracellular H<sub>2</sub>O<sub>2</sub> could target DNA, DNA repair proteins, or mitochondria because

of diminished superoxide dismutase activity (53). New insights may follow from future studies of a very broad range of tumor cells or from microarray analysis of resistant and sensitive cells derived from the same genetic lineage.

H<sub>2</sub>O<sub>2</sub>, as the product of pharmacologic ascorbate concentrations, has potential therapeutic uses in addition to cancer treatment, especially in infections. H<sub>2</sub>O<sub>2</sub> is a potent mammalian antimicrobial defense mechanism (54). Neutrophils generate H<sub>2</sub>O<sub>2</sub> from superoxide, in turn formed by NADPH oxidase-catalyzed reduction of molecular oxygen. There may be particular therapeutic application in patients with chronic granulomatous disease who have diminished superoxide production (55). Old observational animal experiments, although uncontrolled, suggest that *i.v.* ascorbate is effective in some viral infections (56, 57). This finding is also consistent with *in vitro* experiments, in which H<sub>2</sub>O<sub>2</sub> is toxic to hepatitis C (58). Use of ascorbate as an H<sub>2</sub>O<sub>2</sub>-delivery system against sensitive pathogens, viral or bacterial, has substantial clinical implications that deserve rapid exploration.

To proceed clinically in potential treatment of infectious diseases and cancer, clear safety documentation of *i.v.* ascorbate administration is necessary. More than 100 patients have been described, presumably without glucose-6-phosphate dehydrogenase deficiency, who received 10 g or more of *i.v.* ascorbate with no reported adverse effects other than tumor lysis (3, 4, 15, 59). However, these descriptions lack formal safety documentation. Complementary and alternative medicine practitioners worldwide currently use ascorbate *i.v.* in doses as high as 70 g over several hours (14, 15, 59). Because *i.v.* ascorbate is easily available to people who seek it, a phase I safety trial in patients with advanced cancer is justified and underway.

This work was supported in part by the Intramural Research Programs of the National Institute of Diabetes and Digestive and Kidney Diseases and the National Cancer Institute (National Institutes of Health Grant Z01 DK 54506).

- Padayatty, S. J. & Levine, M. (2000) *J. Am. Coll. Nutr.* **19**, 423–425.
- Cameron, E. & Campbell, A. (1974) *Chem. Biol. Interact.* **9**, 285–315.
- Cameron, E. & Pauling, L. (1976) *Proc. Natl. Acad. Sci. USA* **73**, 3685–3689.
- Cameron, E. & Pauling, L. (1978) *Proc. Natl. Acad. Sci. USA* **75**, 4538–4542.
- Creagan, E. T., Moertel, C. G., O'Fallon, J. R., Schutt, A. J., O'Connell, M. J., Rubin, J., & Frytak, S. (1979) *N. Engl. J. Med.* **301**, 687–690.
- Moertel, C. G., Fleming, T. R., Creagan, E. T., Rubin, J., O'Connell, M. J., & Ames, M. M. (1985) *N. Engl. J. Med.* **312**, 137–141.
- Padayatty, S. J., Sun, H., Wang, Y., Riordan, H. D., Hewitt, S. M., Katz, A., Wesley, R. A., & Levine, M. (2004) *Ann. Intern. Med.* **140**, 533–537.
- Levine, M., Conry-Cantilena, C., Wang, Y., Welch, R. W., Washko, P. W., Dhariwal, K. R., Park, J. B., Lazarev, A., Graumlich, J., King, J., et al. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 3704–3709.
- Levine, M., Wang, Y., Padayatty, S. J., & Morrow, J. (2001) *Proc. Natl. Acad. Sci. USA* **98**, 9842–9846.
- Bram, S., Froussard, P., Guichard, M., Jasmin, C., Augery, Y., Sinoussi-Barre, F., & Wray, W. (1980) *Nature* **284**, 629–631.
- Leung, P. Y., Miyashita, K., Young, M., & Tsao, C. S. (1993) *Anticancer Res.* **13**, 475–480.
- Sakagami, H., Satoh, K., Hakeda, Y., & Kumegawa, M. (2000) *Cell. Mol. Biol.* **46**, 129–143.
- Levine, M., Rumsey, S. C., Daruwala, R. C., Park, J. B., & Wang, Y. (1999) *J. Am. Med. Assoc.* **281**, 1415–1423.
- Riordan, N. H., Riordan, H. D., & Casciari, J. J. (2000) *J. Orthomol. Med.* **15**, 201–203.
- Riordan, H. D., Hunnigake, R. B., Riordan, N. H., Jackson, J. J., Meng, X., Taylor, P., Casciari, J. J., Gonzalez, M. J., Miranda-Massari, J. R., Mora, E. M., et al. (2003) *P. R. Health Sci. J.* **22**, 287–290.
- Lee, Y. & Shacter, E. (1997) *J. Clin. Invest.* **89**, 4480–4492.
- Bergsten, P., Amitai, G., Kehrl, J., Dhariwal, K. R., Klein, H. G., & Levine, M. (1990) *J. Biol. Chem.* **265**, 2584–2587.
- Washko, P. W., Wang, Y., & Levine, M. (1993) *J. Biol. Chem.* **268**, 15531–15535.
- Lee, Y. J. & Shacter, E. (1999) *J. Biol. Chem.* **274**, 19792–19798.
- Heeg, K., Reimann, J., Kabelitz, D., Hardt, C., & Wagner, H. (1985) *J. Immunol. Methods* **77**, 237–246.
- Leone, A., Flatow, U., VanHoutte, K., & Steeg, P. S. (1993) *Oncogene* **8**, 2325–2333.
- Zhou, M., Diwu, Z., Panchuk-Voloshina, N., & Haugland, R. P. (1997) *Anal. Biochem.* **253**, 162–168.
- Buettner, G. R. (1990) *Free Radical Res. Commun.* **10**, 5–9.
- Buettner, G. R. & Kiminyo, K. P. (1992) *J. Biochem. Biophys. Methods* **24**, 147–151.
- Long, L. H., Evans, P. J., & Halliwell, B. (1999) *Biochem. Biophys. Res. Commun.* **262**, 605–609.
- Washko, P. W., Hartzell, W. O., & Levine, M. (1989) *Anal. Biochem.* **181**, 276–282.
- Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goetze, N. M., Olson, B. J., & Klenk, D. C. (1985) *Anal. Biochem.* **150**, 76–85.
- Englert, R. P. & Shacter, E. (2002) *J. Biol. Chem.* **277**, 20518–20526.
- Corpe, C. P., Lee, J. H., Kwon, O., Eck, P., Narayanan, J., Kirk, K. L., & Levine, M. (2005) *J. Biol. Chem.* **280**, 5211–5220.
- Day, B. J., Fridovich, I., & Crapo, J. D. (1997) *Arch. Biochem. Biophys.* **347**, 256–262.
- Burns, J. A., Butler, J. C., Moran, J., & Whitesides, G. M. (1991) *J. Org. Chem.* **56**, 2648–2650.
- Buettner, G. R. (1986) *Free Radical Res. Commun.* **1**, 349–353.
- L'Epplattienier, F., Murase, I., & Martell, A. E. (1967) *J. Am. Chem. Soc.* **89**, 837–843.
- Halliwell, B. (1990) *Free Radical Res. Commun.* **9**, 1–32.
- Samuni, A. M., Afeworki, M., Stein, W., Yordanov, A. T., DeGraff, W., Krishna, M. C., Mitchell, J. B., & Brechbiel, M. W. (2001) *Free Radical Biol. Med.* **30**, 170–177.
- Fridovich, I. (1995) *Annu. Rev. Biochem.* **64**, 97–112.
- Wang, X., Liu, J., Yokoi, I., Kohno, M., & Mori, A. (1992) *Free Radical Biol. Med.* **12**, 121–126.
- Chance, B., Sies, H., & Boveris, A. (1979) *Physiol. Rev.* **59**, 527–605.
- Brown, J. M., Grosso, M. A., Terada, L. S., Beecher, C. J., Toth, K. M., Whitman, G. J., Harken, A. H., & Repine, J. E. (1989) *Am. J. Physiol.* **256**, H584–H588.
- Guemouri, L., Artur, Y., Herbeth, B., Jeandel, C., Cuny, G., & Siest, G. (1991) *Clin. Chem.* **37**, 1932–1937.
- Motoyama, S., Saito, S., Inaba, H., Kitamura, M., Minamiya, Y., Suzuki, H., Saito, R., Kamata, S., Nakae, H., & Ogawa, J. (2000) *Liver* **20**, 200–208.
- Frossard, M., Blank, D., Joukhadar, C., Bayegan, K., Schmid, R., Luger, A., & Muller, M. (2005) *Diabet. Med.* **22**, 56–60.
- Han, S. S., Kim, K., Hahn, E. R., Lee, S. J., Surh, Y. J., Park, H. K., Kim, W. S., Jung, C. W., Lee, M. H., Park, K., et al. (2004) *J. Cell. Biochem.* **93**, 257–270.
- Park, S., Han, S. S., Park, C. H., Hahn, E. R., Lee, S. J., Park, H. K., Lee, S. H., Kim, W. S., Jung, C. W., Park, K., et al. (2004) *Int. J. Biochem. Cell Biol.* **36**, 2180–2195.
- Koh, W. S., Lee, S. J., Lee, H., Park, C., Park, M. H., Kim, W. S., Yoon, S. S., Park, K., Hong, S. I., Chung, M. H., et al. (1998) *Anticancer Res.* **18**, 2487–2493.
- Calderon, P. B., Cadrobbi, J., Marques, C., Hong-Ngoc, N., Jamison, J. M., Gilloteaux, J., Summers, J. L., & Taper, H. S. (2002) *Curr. Med. Chem.* **9**, 2271–2285.
- Arakawa, N., Nemoto, S., Suzuki, E., & Otsuka, M. (1994) *J. Nutr. Sci. Vitaminol. (Tokyo)* **40**, 219–227.
- Sestili, P., Brandi, G., Brambilla, L., Cattabeni, F., & Cantoni, O. (1996) *J. Pharmacol. Exp. Ther.* **277**, 1719–1725.
- Clement, M. V., Ramalingam, J., Long, L. H., & Halliwell, B. (2001) *Antioxid. Redox. Signal.* **3**, 157–163.
- Weinberger, A. & Simkin, P. A. (1989) *Semin. Arthritis Rheum.* **19**, 66–76.
- Buettner, G. R. & Jurkiewicz, B. A. (1996) *Radiat. Res.* **145**, 532–541.
- Antunes, F. & Cadenas, E. (2000) *FEBS Lett.* **475**, 121–126.
- Oberley, L. W. (2001) *Antioxid. Redox. Signal.* **3**, 461–472.
- Babior, B. M. (2000) *Am. J. Med.* **109**, 33–44.
- Heyworth, P. G., Cross, A. R., & Curtnite, J. T. (2003) *Curr. Opin. Immunol.* **15**, 578–584.
- Edwards, W. C. (1968) *Vet. Med. Small Anim. Clin.* **63**, 696–698.
- Leveque, J. I. (1969) *Vet. Med. Small Anim. Clin.* **64**, 997–999.
- Choi, J., Lee, K. J., Zheng, Y., Yamaga, A. K., Lai, M. M., & Ou, J. H. (2004) *Hepatology* **39**, 81–89.
- Riordan, N. H., Riordan, H. D., Meng, X., Li, Y., & Jackson, J. A. (1995) *Med. Hypotheses* **44**, 207–213.